Moleculin Biotech Inc (MBRX) concluded trading on Wednesday at a closing price of $0.67, with 11.01 million shares of worth about $7.37 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -75.69% during that period and on June 04, 2025 the price saw a loss of about -19.83%. Currently the company’s common shares owned by public are about 14.13M shares, out of which, 14.01M shares are available for trading.
Stock saw a price change of -24.50% in past 5 days and over the past one month there was a price change of -35.24%. Year-to-date (YTD), MBRX shares are showing a performance of -60.38% which decreased to -85.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.40 but also hit the highest price of $4.90 during that period. The average intraday trading volume for Moleculin Biotech Inc shares is 454.83K. The stock is currently trading -28.62% below its 20-day simple moving average (SMA20), while that difference is down -28.99% for SMA50 and it goes to -62.04% lower than SMA200.
Moleculin Biotech Inc (NASDAQ: MBRX) currently have 14.13M outstanding shares and institutions hold larger chunk of about 10.46% of that.
The stock has a current market capitalization of $9.52M and its 3Y-monthly beta is at 1.56. It has posted earnings per share of -$5.80 in the same period. It has Quick Ratio of 1.35 while making debt-to-equity ratio of 11.25. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MBRX, volatility over the week remained 11.07% while standing at 6.34% over the month.
Stock’s fiscal year EPS is expected to rise by 71.73% while it is estimated to increase by 2.61% in next year. EPS is likely to grow at an annualized rate of 37.34% for next 5-years, compared to annual growth of 26.36% made by the stock over the past 5-years.
Coverage by Oppenheimer stated Moleculin Biotech Inc (MBRX) stock as an Outperform in their note to investors on July 18, 2022, suggesting a price target of $14 for the stock.
